Brokerages predict that Theravance Biopharma Inc (NASDAQ:TBPH) will report sales of $3.71 million for the current quarter, Zacks reports. Two analysts have made estimates for Theravance Biopharma’s earnings. The highest sales estimate is $4.20 million and the lowest is $3.23 million. Theravance Biopharma reported sales of $5.69 million during the same quarter last year, which would suggest a negative year over year growth rate of 34.8%. The company is scheduled to announce its next earnings results on Monday, February 26th.
On average, analysts expect that Theravance Biopharma will report full-year sales of $3.71 million for the current fiscal year, with estimates ranging from $13.89 million to $14.90 million. For the next financial year, analysts forecast that the firm will report sales of $34.52 million per share, with estimates ranging from $22.93 million to $46.10 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Theravance Biopharma.
Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.22) by ($0.05). Theravance Biopharma had a negative net margin of 1,604.87% and a negative return on equity of 99.43%.
Large investors have recently bought and sold shares of the stock. QS Investors LLC bought a new stake in Theravance Biopharma during the 2nd quarter valued at $100,000. Ameritas Investment Partners Inc. raised its holdings in Theravance Biopharma by 6.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,865 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 230 shares during the last quarter. BNP Paribas Arbitrage SA raised its holdings in Theravance Biopharma by 570.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 5,151 shares of the biopharmaceutical company’s stock valued at $205,000 after buying an additional 4,383 shares during the last quarter. Amalgamated Bank bought a new position in Theravance Biopharma in the 2nd quarter worth $214,000. Finally, Veritable L.P. bought a new position in Theravance Biopharma in the 2nd quarter worth $275,000. Institutional investors own 86.01% of the company’s stock.
Shares of Theravance Biopharma (TBPH) opened at $29.64 on Tuesday. Theravance Biopharma has a 12 month low of $23.15 and a 12 month high of $43.44. The stock has a market cap of $1,532.21, a price-to-earnings ratio of -5.73 and a beta of 2.10. The company has a quick ratio of 7.21, a current ratio of 7.53 and a debt-to-equity ratio of 1.21.
TRADEMARK VIOLATION WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/01/23/analysts-expect-theravance-biopharma-inc-tbph-will-post-quarterly-sales-of-3-71-million.html.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.